Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul Robert Eastwood is active.

Publication


Featured researches published by Paul Robert Eastwood.


Bioorganic & Medicinal Chemistry Letters | 2003

Mapping the kinase domain of Janus Kinase 3.

Christopher Adams; David J. Aldous; Shelley Amendola; Paul Lindsay Rhône-Poulenc Rorer Ltd Bamborough; Colin Bright; Sarah J. Crowe; Paul Robert Eastwood; Garry Fenton; Martyn Foster; Trevor K.P. Harrison; Sue King; Justine Lai; Christopher Lawrence; Jean-Philippe Letallec; Clive McCarthy; Neil Moorcroft; Kenneth Page; Sudha Rao; Shazia Sadiq; Keith Smith; John E. Souness; Sukanthini Thurairatnam; Mark Vine; Barry Wyman

The utilization and impact of parallel synthesis on lead exploration around initial hit oxindole (1) are described. The emergent SAR, analogue design and functional impact will also be detailed.


Tetrahedron Letters | 2000

A versatile synthesis of 4-aryl tetrahydropyridines via palladium mediated Suzuki cross-coupling with cyclic vinyl boronates

Paul Robert Eastwood

Abstract A simple preparation of cyclic vinyl boronates derived from the vinyl triflates of N-protected tetrahydropyridines is described. Suzuki coupling of the boronates with aryl bromides, iodides and triflates proceeds in good yield to give 4-aryl tetrahydropyridines.


Bioorganic & Medicinal Chemistry Letters | 2010

Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists.

Paul Robert Eastwood; Jacob González; Sergio Paredes; Arsenio Nueda; Teresa Doménech; Joan Albertí; Bernat Vidal

The synthesis and SAR of a series of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent A(2B) adenosine receptor antagonists is described. Several compounds showed good selectivity versus other adenosine receptors. The potent and selective analogue 9 was shown to have good oral bioavailability in the rat.


Bioorganic & Medicinal Chemistry Letters | 2011

Indolin-2-one p38α inhibitors I: Design, profiling and crystallographic binding mode

Paul Robert Eastwood; Jacob González; Elena Gómez; Bernat Vidal; Francisco Caturla; Ramón Roca; Cristina Balagué; Adelina Orellana; María Domínguez

The use of structure-based design and molecular modeling led to the discovery of indolin-2-one derivatives as potent and selective p38α inhibitors. The predicted binding mode was confirmed by X-ray crystallography.


Bioorganic & Medicinal Chemistry Letters | 2012

Novel triazolopyridylbenzamides as potent and selective p38α inhibitors

Josep Aiguadé; Cristina Balagué; Inés Carranco; Francisco Caturla; María Domínguez; Paul Robert Eastwood; Cristina Esteve; Jacob González; Wenceslao Lumeras; Adelina Orellana; Sara Preciado; Ramón Roca; Laura Vidal; Bernat Vidal

A new class of p38α inhibitors based on a biaryl-triazolopyridine scaffold was investigated. X-ray crystallographic data of the initial lead compound cocrystallised with p38α was crucial in order to uncover a unique binding mode of the inhibitor to the hinge region via a pair of water molecules. Synthesis and SAR was directed towards the improvement of binding affinity, as well as ADME properties for this new class of p38α inhibitors and ultimately afforded compounds showing good in vivo efficacy.


Bioorganic & Medicinal Chemistry Letters | 2010

Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement.

Paul Robert Eastwood; Jacob González; Sergio Paredes; Silvia Fonquerna; Arantxa Cardús; Juan Antonio Alonso; Arsenio Nueda; Teresa Doménech; Raquel F. Reinoso; Bernat Vidal

Several new potent and selective A(2B) adenosine receptor antagonists have been prepared in which the aryl-amide moiety of the lead series, exemplified by 1a, has been replaced by bioisosteric bicyclic moieties. Although the majority of compounds had generally improved microsomal stability as compared to 1a, this was not translated into overall improvements in the pharmacokinetic profiles of a representative set of compounds.


Bioorganic & Medicinal Chemistry Letters | 2011

Indolin-2-one p38α inhibitors III: bioisosteric amide replacement.

Paul Robert Eastwood; Jacob González; Elena Gómez; Francisco Caturla; Nuria Aguilar; Marta Mir; Josep Aiguadé; Victor Giulio Matassa; Cristina Balagué; Adelina Orellana; María Domínguez

Crystallographic structural information was used in the design and synthesis of a number of bioisosteric derivatives to replace the amide moiety in a lead series of p38α inhibitors which showed general hydrolytic instability in human liver preparations. Triazole derivative 13 was found to have moderate bioavailability in the rat and demonstrated potent in-vivo activity in an acute model of inflammation.


Archive | 2001

Arylmethylamine derivatives for use as tryptase inhibitors

Peter Charles Astles; Paul Robert Eastwood; Olivier Houille; Julian Levell; Heinz W. Pauls; Mark Czekaj; Guyan Liang; Yong Gong; James Pribish; Kent Neuenschwander


Archive | 2005

Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)

Philip M. Weintraub; Paul Robert Eastwood; Shujaath Mehdi; David Stefany; Kwon Yon Musick; Neil Moorcroft; Sungtaek Lim; John Z. Jiang; Hartmut Rütten; Stefan Peukert; Uwe Schwahn


Archive | 2004

Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)

John Z. Jiang; Jack Roger Koehl; Shujaath Mehdi; Neil Moorcroft; Kwon Yon Musick; Philip M. Weintraub; Paul Robert Eastwood

Collaboration


Dive into the Paul Robert Eastwood's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jacob González

Technical University of Madrid

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge